Keep Data in Biosimilar Labeling Clear
Carlos Sattler, MD, is vice president of clinical development and medical affairs at Sandoz. The op-ed below was first published on Morning Consult.
Science and medicine have dramatically changed how we manage and treat complex diseases that ravage our families and burden our economy. The nation’s medicine cabinet was once only filled with small molecule drugs derived from a chemical process—the pills patients pick up at their local pharmacies. The treatments of the present and future, however, are heavily reliant on biological therapies that are produced from living organisms and are often administered in doctor’s offices as an injection or through an IV.
Read the full piece by clicking on the link.